Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Zacks.com featured highlights include Carlisle Companies, ResMed, Booz Allen Hamilton and CrediCorp

2024-05-28
Carlisle Companies, ResMed, Booz Allen Hamilton and CrediCorp are part of the Zacks Screen of the Week article.

ResMed (RMD) Up 16.3% Since Last Earnings: Will it Continue?

2024-05-27
Investors are optimistic about ResMed (RMD) led by strong growth in the U.S. mask and accessories business and its cloud-connected platforms.

Stereotaxis (STXS) Gets CE Recertification for Approved Products

2024-05-27
Stereotaxis' (STXS) receives updated EU Quality Management System Certificate, which demonstrates compliance with MDR.

(RMD) - Analyzing ResMed's Short Interest

2024-05-27
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Charles River (CRL) Banks on RMS Growth Amid Competition

2024-05-24
Charles River's (CRL) RMS arm sees lesser impact on demand than other life science sectors despite macroeconomic challenges in China.

Scoop up These 4 GARP Stocks to Receive Handsome Returns

2024-05-24
The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. CSL, RMD, BAH and BAP are some stocks that hold promise.

ResMed : Third Quarter 2024 Transcript

2024-05-23
REFINITIV STREETEVENTS EDITED TRANSCRIPT Q3 2024 Resmed Inc Earnings Call EVENT...

Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy

2024-05-23
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive sleep apnea (OSA)Prevalence of OSA in the United States expected to increase 26.7% in men and women aged 30 –70Real-world trends of glucagon-like peptide-1 (GLP-1) receptor agonist and PAP therapy use show patients who were adherent to their GLP-1 medication had higher levels of PAP therapy use than those

Here's How Much a $1000 Investment in ResMed Made 10 Years Ago Would Be Worth Today

2024-05-23
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

ResMed issues new research, insights into effectiveness of PAP therapy

2024-05-23
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.